{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'PFS1 is planned to test at either the interim analysis or final analysis when OS is rejected.', 'ORR and DCR will be tested only once after both OS and PFS1 are rejected (at either interim', 'analysis or final analysis) and the test statistics will be computed from the interim data. DCR', 'will be tested after ORR is rejected. The details about the significance levels at interim', 'analysis and final analysis for each efficacy endpoints (OS, PFS1, ORR and DCR) are', 'specified in SAP.', '7.4.1', 'Analysis of Primary Endpoint', '7.4.1.1 Primary Analysis', 'The primary efficacy endpoint of os will be analyzed using the log-rank test stratified by', 'ECOG PS (0 vs 1), regions of the world (Western EU, US or the rest of world) and liver', 'metastasis (yes or no). Randomized treatment and the strata used for randomization will be', 'used for the analysis. In addition, the stratified Cox proportional hazard model will be used to', 'estimate the hazard ratio and the corresponding 95% confidence interval. The median OS will', 'be estimated using the Kaplan-Meier method and will be reported along with the', 'corresponding 95% confidence interval by treatment arm.', 'The primary analysis will be performed using the FAS.', '7.4.1.2 Sensitivity Analysis', 'Additional analyses such as unstratified log-rank test and os analyses adjusting the crossover', 'effect may be conducted, if appropriate. Details will be specified in the SAP.', '7.4.2', 'Analysis of Secondary Enppoints', '7.4.2.1 Progression Free Survival', 'For each subject, PFS1 is defined as the time from the date of randomization until the date of', 'radiological disease progression (per RECIST V1.1), or until death due to any cause. If a', 'subject has neither progressed nor died, the subject will be censored at the date of last', 'radiological assessment. Subjects who receive any further anticancer therapy for the disease', 'before radiological progression will be censored at the date of the last radiological', 'assessment before the anticancer therapy started. In addition, subjects who have PD or death', 'after 2 or more missed disease assessments will be censored at the last disease assessment', 'prior to the 2 or more missed disease assessments.', 'The efficacy endpoint of PFS1 will be analyzed using the log-rank test stratified by ECOG', 'PS (0 VS 1), regions of the world (Western EU, US or the rest of world) and liver metastasis', '(yes or no). Randomized treatment and the strata used for randomization will be used for the', 'analysis. In addition, stratified Cox proportional hazard model will be used to estimate the', 'hazard ratio and the corresponding 95% confidence interval. The median PFS1 will be', 'estimated using the Kaplan-Meier method and will be reported along with the corresponding', '95% confidence interval by treatment arm.', 'The primary analysis will be performed using the FAS. Additional sensitivity analyses for', 'PFS1 will also be performed. Details will in specified in the SAP', '14 Sep 2020', 'Astellas', 'Page 87 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '7.4.2.2 Overall Response Rate', 'The overall response rate (ORR) is defined as the proportion of subjects with complete or', 'partial objective response based on the RECIST V1.1. The comparison of ORR between Arm', 'A and Arm B will be performed using a stratified CMH test. Same stratification factors used', 'in time to event analyses will be used for the stratified CMH test. The difference in response', 'rates between the treatment arms will be estimated along with the corresponding 95%', 'confidence interval. In addition, ORR for each arm will be estimated and corresponding 95%', 'confidence interval will be constructed. The primary analysis will be performed using the', 'RES.', '7.4.2.3 Duration of Response', 'Duration of Response (DOR) is defined as the time from the date of the first response CR/PR', 'per RECIST V1.1 (whichever is first recorded) that is subsequently confirmed as assessed by', 'investigator to the date of radiological progression or date of death for subjects who achieved', 'CR or PR. If a subject has not progressed or died, the subject will be censored at the date of', 'last radiological assessment or at the date of first CR/PR if no other post-baseline radiological', 'assessment is available after the first CR/PR. Subjects who receive any further anti-cancer', 'therapy for the disease before radiological progression will be censored at the date of the last', 'radiological assessment before the anticancer therapy started. In addition, subjects who have', 'PD or death after 2 or more missed disease assessments will be censored at the last disease', 'assessment prior to the 2 or more missed disease assessments.', 'The median DOR will be estimated using the Kaplan-Meier method and will be reported', 'along with the corresponding 95% confidence interval by treatment arm.', '7.4.2.4 Disease Control Rate (DCR)', 'The DCR is defined as the proportion of subjects with a complete or partial objective', 'response or a stable disease based on RECIST V1.1. The comparison of DCR between Arm', 'A and Arm B will be performed using a stratified CMH test. Same stratification factors used', 'in time to event analyses will be used for the stratified CMH test. The difference in response', 'rates between the treatment arms will be estimated along with the corresponding 95%', 'confidence interval. In addition, DCR for each arm will be estimated and corresponding 95%', 'confidence interval will be constructed. The primary analysis will be performed using the', 'RES.', '7.4.2.5 QOL and PRO Parameters', 'Descriptive QOL and PRO analyses will be performed on the FAS. Completion rate for each', 'questionnaire will be summarized. Additional analyses will be discussed in detail in the', 'statistical analysis plan.', '7.4.3', 'Subgroup Analysis', 'Using FAS, the analysis for OS, PFS1 and ORR will be repeated by ECOG PS (0 vs 1),', 'regions of the world, and liver metastasis respectively.', '14 Sep 2020', 'Astellas', 'Page 88 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}